Wednesday, October 14, 2020

MIT Center for Biomedical Innovation Webinar Series* on Biotechnology in the Age of COVID-19

Biopharmaceutical Business Continuity in the COVID-19 Era”
October 14th, 11:00 am – 1:30 m EST

[BioMAN & CAACB Members Only]

Click for current BioMAN Member & CAACB Member companies.
For more information on how to register, please contact Karyn Glemaud-Anis (kglemaud@mit.edu)

The biopharmaceutical manufacturing industry is essential for maintaining public health by providing a safe and sustainable supply of biologic medicines. Not only has it continued to operate during the pandemic, it has greatly expanded its activities to directly address COVID-19 by developing and manufacturing treatments and vaccines, in addition to the normal portfolio of products. Since COVID-19 spread worldwide in 2020, supply chains have come under increasing pressure, with areas of concern including shortages of raw materials, geographical barriers to distribution, and competition. Business continuity may also be impacted by factors such as the rapid redirection of resources toward vaccines, adjuvants or therapeutics. Maintaining biomanufacturing continuity in the face of these challenges is vitally important. This webinar will feature presentations from industry sharing experiences of how they maintain manufacturing and business continuity, as well as a panel discussion about what we have learned from COVID-19 that can enhance industry response to future pandemics. The webinar will address the following topics:

Disruptions to Manufacturing Continuity Due to Supply Chain

This topic area will focus on how COVID-19 specifically impacted supply chains of raw materials and components and will include:

– Issues encountered in accessing materials or services needed to maintain manufacturing operations
– The strategic response to supply chain challenges, such as identification of qualified second sources or secondary vendors, and alternate transportation of materials
– What supply chain continuity plans looked like before the pandemic and how they are being updated due to recent experiences

Disruptions to Business Continuity Beyond Supply Chain

This topic area will focus on disruptions to business continuity in internal operations and/or external collaborations as a result of COVID-19 that were beyond supply chain issues and will include:

– Reprioritization of product manufacturing due to changes in demand
– Redirection of resources to COVID-19 vaccine or therapeutic development activities
– Impacts to biomanufacturing operations due to personnel issues
– Changes to manufacturing sites due to COVID-19
– Long-range impacts to product development pipelines

*Because our Spring Workshops were cancelled due to the COVID-19 pandemic, we created a webinar series, Biotechnology in the Age of COVID-19, for our BioMAN and CAACB consortia members, as well as members of the biomanufacturing community at MIT. The goal of these webinars is to address issues around the biopharmaceutical industry’s multi-faceted response to the pandemic and the impact on manufacturing operations. The first webinar, The Impact of SARS-CoV-2 on Biomanufacturing Operations, was held on April 22nd and focused on strategies to prevent process and product contamination by SARS-CoV-2 and to ensure continuity of manufacturing during the pandemic. The second webinar, Manufacturing Treatments and Vaccines for COVID-19, was held on June 10th and focused on the challenges of developing drugs to combat the pandemic in the face of accelerated product development timelines and the need for manufacturing on a global scale.